Aging
Navigate
Submit an Article
Research Paper|Volume 12, Issue 10|pp 9188—9204

A three-lncRNA signature predicts clinical outcomes in low-grade glioma patients after radiotherapy

Wanzun Lin1, Zongwei Huang2, Yanyan Xu3, Xiaochuan Chen2, Ting Chen4, Yuling Ye2, Jianming Ding1, Zhangjie Chen4, Long Chen5, Xianxin Qiu6, Sufang Qiu2
  • 1Department of Radiation Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China
  • 2Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China
  • 3Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • 4Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
  • 5Division of Neurocritical Care, Huashan Hospital, Fudan University, Shanghai, China
  • 6Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China
* Equal contribution
Received: November 21, 2019Accepted: April 17, 2020Published: May 26, 2020
https://doi.org/10.18632/aging.103189

Copyright © 2020 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Although radiation therapy (RT) plays a critical role in the treatment of low-grade glioma (LGG), many patients suffer from adverse effects without experiencing survival benefits. In various carcinomas, long non-coding RNAs (lncRNAs) contribute to pathogenic processes, including tumorigenesis, metastasis, chemoresistance, and radioresistance. Currently, the role of lncRNAs in the radiosensitivity of LGG is largely unknown. Here, we downloaded clinical data for 167 LGG patients from The Cancer Genome Atlas database and divided them between radiosensitive and radioresistant groups based on their clinical outcomes after receiving radiotherapy. We identified 37 lncRNAs that were differentially expressed (DElncRNAs) between the groups. Functional enrichment analysis revealed that their potential target mRNAs were mainly enriched in the PI3K-Akt and MAPK signaling pathways and in DNA damage response. Kaplan-Meier survival analysis revealed that increased expression of six lncRNAs was significantly associated with radiosensitivity. We then developed a risk signature based on three of the DElncRNAs that served as an independent biomarker for predicting LGG patient outcomes after radiotherapy. In vitro experiments further validated the biological function of these lncRNAs on low-grade glioma radiation response.